Q:
Are we doing any harm by giving antibiotics to the mother in preterm labor or to the preterm baby? Dr. Jobe:
I do not think so. Most of the time, we really do not know what we are treating, and there are no compelling data that antibiotic therapy prevents prematurity. The general practice of giving antibiotics is probably entirely reasonable. About the use of postnatal antibiotics, our practice in these tiny babies is that if they do not have a positive blood culture in 48 hours, they are off antibiotics.
Does pre-eclampsia accelerate lung maturity via an inflammatory response? Dr. Jobe:
Interesting idea. It turns out from several large data sets that, actually, pre-eclampsia does not induce early lung maturation.
Are there any benefits to using postnatal steroids? Dr. Jobe:
All of us clearly have seen babies who respond strikingly to postnatal steroids. The question is benefit versus risk. The problem is that we are scared of using postnatal steroids because of the follow-up data that are available. The follow-up data that are available are not of very good quality. If you put that kind of information with the Cochrane meta-analysis, basically what you get is the sense that using postnatal steroids later in the course of the development of BPD is probably considerably less risky than using it very soon after delivery.
So what that means to me and to Professor Henry Halliday is to use steroids at 2 weeks or later, if you think they need them. Another thing we know is that babies who respond, respond quickly, and babies who do not respond, just never respond. It seems to me a rational approach is that if you have a baby who is ''stuck'' on a ventilator and developing progressive lung injury, it is reasonable to use a low-dose, short course of postnatal steroids, 5 to 10 days at 0.05 to 0.2 mg at 2 weeks or older. That is a rational strategy that ends up treating 15% or less of your <1000 g babies with postnatal steroids.
There is lot of interest in synthetic surfactants. The recent surfactant that is being evaluated is surfaxin/lucinactant (Surfaxin s , Discovery Laboratories, Inc., Warrington, PA). From your data, it looks more like an SP-C analog rather than an SP-B analog. Is it more like an SP-C or SP-B analog? Dr. Curstedt: In our hands, it is an SP-C analog based on the studies we have done in our laboratory. SP-B is very complex and it is very difficult to synthesize. It is impossible today to ave a recombinant SP-B-based surfactant.
Do you think a recombinant SP-C-based synthetic surfactant will become available for clinical use? Dr. Curstedt: At present, we have venticute (Venticute s , Byk Gulden, Konstanz, Germany), which is an SP-C analog-based surfactant. It works very well in preterm animal models. However, the drug developers are interested in evaluating it for use in ARDS rather than in neonatal RDS.
